...
首页> 外文期刊>Alimentary pharmacology & therapeutics. >Diastolic dysfunction on echocardiography does not predict survival after transjugular intrahepatic portosystemic stent‐shunt in patients with cirrhosis
【24h】

Diastolic dysfunction on echocardiography does not predict survival after transjugular intrahepatic portosystemic stent‐shunt in patients with cirrhosis

机译:超声心动图的舒张性功能障碍在肝硬化患者患者外节内肝内雌甾型电池分流后未预测存活

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Summary Background Cardiac dysfunction is frequently observed in patients with cirrhosis. There remains a paucity of data from routine clinical practice regarding the role of echocardiography in the pre‐assessment of transjugular intrahepatic portosystemic stent‐shunt. Aim Our study aimed to investigate if echocardiography parameters predict outcomes after transjugular intrahepatic portosystemic stent‐shunt insertion in cirrhosis. Methods Patients who underwent echocardiography and transjugular intrahepatic portosystemic stent‐shunt insertion at the liver unit (Birmingham, UK) between 1999 and 2016 were included. All echocardiography measures (including left ventricle ejection fraction; early maximal ventricular filling/late filling velocity ratio, diastolic dysfunction as per British Society of Echocardiography guidelines) were independently reviewed by a cardiologist. Predictors of 30‐day and overall transplant free‐survival were assessed. Results One Hundred and Seventeen patients with cirrhosis (median age 56?years; 54% alcohol; Child‐Pugh B/C 71/14.5%; Model For End‐Stage Liver Disease 12) underwent transjugular intrahepatic portosystemic stent‐shunt for ascites (n?=?78) and variceal haemorrhage (n?=?39). Thirty‐day and overall transplant‐free survival was 90% (n?=?105) and 31% (n?=?36), respectively, over a median 663 (IQR 385‐2368) days follow‐up. Model for End‐Stage Liver Disease ( P ??0.001) and Child‐Pugh Score ( P ?=?0.002) significantly predicted 30‐day and overall transplant‐free survival. Model for End‐Stage Liver Disease ≥15 implied three‐fold risk of death. Six per cent (n?=?7) of patients pre‐transjugular intrahepatic portosystemic stent‐shunt had a history of ischaemic heart disease and 34% (n?=?40) had 1 or more cardiovascular disease risk factors. Fifty per cent (n?=?59) had an abnormal echocardiogram and 33% (n?=?39) had grade 1‐3 diastolic dysfunction. On univariate analysis none of the echocardiography measures pre‐intervention were related to 30‐day or overall transplant‐free survival post‐transjugular intrahepatic portosystemic stent‐shunt. Conclusions Ventricular, in particular diastolic dysfunction in patients with cirrhosis does not predict survival after transjugular intrahepatic portosystemic stent‐shunt insertion. Model for End‐Stage Liver Disease and Child‐Pugh scores remain the best predictors of survival. Further prospective study is required to clarify the role of routine echocardiography prior to transjugular intrahepatic portosystemic stent‐shunt insertion.
机译:发明内容肝硬化患者经常观察到背景背景心功能障碍。仍然存在来自常规临床实践的数据,了解超声心动图在古代肝内囊体系上分流的预评估中的作用。目的我们的研究旨在调查超声心动图参数是否预测肝硬化中的颈静脉内肝内系统支架插入后的结果。方法包括在1999年至2016年间肝脏单位(伯明翰,英国)接受超声心动图和古典肝内雌胸体系上的患者的患者。所有超声心动图措施(包括左心室射血分数;早期最大心室填充/晚期灌装速度比,根据英国超声心动图指南的舒张功能障碍)被心脏病专门审查。评估了30天和整体移植自来源的预测因子。结果肝硬化百年和17名患者(中位数56岁;年龄; 54%酒精;儿童PUGH B / C 71 / 14.5%;末期肝病的模型12)接受了腹水的外节肝内囊体系分流器(n ?=?78)和静脉血回血(n?= 39)。在中位663(IQR 385-2368)日随访中,30天和无总体移植存活率分别为90%(n?=Δ105)和31%(n?= 36)天。终末期肝病模型(P?&?0.001)和Child-Pugh得分(P?= 0.002)显着预测30天和整体移植的存活。末期肝病模型≥15暗示死亡的三倍风险。六百分之(N?=?7)患者预讲犹太管肝内雌激素的支架分流器的缺血性心脏病历史,34%(n?= 40)有1个或更多的心血管疾病风险因素。五十百分之五十(n?=Δ59)具有异常超声心动图,33%(n?= 39)具有1-3级舒张功能障碍。在单变量分析上,没有超声心动图测量预干预的介入与后颈内肝内雌甾型支架的30天或全整体移植生存期有关。结论心室,特别是肝硬化患者的舒张性功能障碍在外节内肝内囊体支架分流器插入后不能预测存活。末期肝病和Child-Pugh分数的模型仍然是生存的最佳预测因子。需要进一步的前瞻性研究来阐明常规超声心动图在外节内肝内雌激酶支架分流插入之前的常规超声心动图的作用。

著录项

  • 来源
  • 作者单位

    Liver UnitQueen Elizabeth University HospitalBirmingham UK;

    Liver UnitQueen Elizabeth University HospitalBirmingham UK;

    Liver UnitQueen Elizabeth University HospitalBirmingham UK;

    Medical StatisticsInstitute of Translational Medicine Queen Elizabeth University;

    Liver UnitQueen Elizabeth University HospitalBirmingham UK;

    Liver UnitQueen Elizabeth University HospitalBirmingham UK;

    Department of Diagnostic ImagingNational University Hospital (NUH)Singapore Singapore;

    Department of Interventional RadiologyQueen Elizabeth University HospitalBirmingham UK;

    Department of Interventional RadiologyQueen Elizabeth University HospitalBirmingham UK;

    Department of Interventional RadiologyQueen Elizabeth University HospitalBirmingham UK;

    Department of Interventional RadiologyQueen Elizabeth University HospitalBirmingham UK;

    Department of CardiologyQueen Elizabeth University HospitalBirmingham UK;

    Liver UnitQueen Elizabeth University HospitalBirmingham UK;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药理学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号